← All trials
NCT02082860
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2012
- Primary completion
- Jul 1, 2014
- Completion date
- Nov 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 8
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Digna Biotech S.L.Lead sponsor
- Universidad Complutense de MadridOverall official - principal investigator
- Digna Biotech S.L.Study chair
- Porphyria Centre SwedenCollaborator
- UniQure N.V.Collaborator
- Clinica Universidad de NavarraOverall official - principal investigator
- Clinica Universidad de NavarraCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.